Can a bioreactor predict ovarian cancer chemo success?
NCT ID NCT07461207
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aims to see if a special device called a U-Cup bioreactor can predict how well standard chemotherapy will work in women with high-grade ovarian cancer. Researchers will take tumor samples from 120 patients before treatment and test them in the lab. The goal is to find out which patients are likely to respond and which might need different therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a lab test that helps doctors choose the right chemotherapy for each ovarian cancer patient.
- What could go wrong
- This is an early observational study, not a treatment trial. The tool may not accurately predict responses in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Bologna, 40138, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.